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Abstract
Objective To develop and validate new regret scales and examine
whether a decision aid aﬀects diﬀerent aspects of regret in the
treatment choice for prostate cancer.
Methods This was a multicentre trial (three sites) with imbalanced
randomization (1 : 2). From 2008 to 2011, patients with localized
prostate cancer were randomized 1 : 2 to usual care (N = 77) or
usual care plus a decision aid presenting risks and beneﬁts of diﬀer-
ent treatments (N = 163). The treatments were surgery and (exter-
nal or interstitial) radiotherapy. Regret was assessed before, and 6
and 12 months after treatment, using the Decisional regret scale by
Brehaut et al. (Medical Decision Making, 23, 2003, 281), and three
new scales focusing on process, option and outcome regret. The
relation between decision aid and regret was analysed by ANOVA.
Results The concurrent validity of the new regret scales was con-
ﬁrmed by correlations between regret and anxiety, depression,
decision evaluation scales and health-related quality of life. With a
decision aid, patient participation was increased (P = 0.002), but
regret was not. If anything, in patients with serious morbidity the
decision aid resulted in a trend to less option regret and less
Brehaut regret (P = 0.075 and P = 0.061, with eﬀect sizes of 0.35
and 0.38, respectively). Exploratory analyses suggest that high-risk
patients beneﬁtted most from the decision aid.
Conclusion The new regret scales may be of value in distinguishing
separate aspects of regret. In general, regret was not aﬀected by
the decision aid. In patients with serious morbidity, a trend to
lower option regret with a decision aid was observed.
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Introduction
For patients facing a choice between diﬀerent
treatment options, decision aids have been
developed. However, these tools are still not
widely implemented in daily oncology practice,
possibly for fear of increasing anxiety1 or
uncertainty.2 The fear of negative eﬀects, for
example reducing hope or increasing regret,
makes some physicians hesitant to share all
outcome information,3 despite the fact that
studies did not ﬁnd negative eﬀects. When
patients with cancer were informed about a
poor prognosis, hope was maintained.4 And
when they were involved in the treatment
choice, regret was not increased.5–7
This study focuses in more detail on diﬀerent
aspects of regret. To date, regret has been
mainly studied using the Brehaut regret scale8
(a questionnaire on decisional regret), or by
separate questions such as ‘Would you choose
the same treatment again?’.9 Such measures
mainly focus on which treatment option was
chosen. With respect to decision making, how-
ever, three types of regret have been distin-
guished:10 (i) process regret, referring to the
process leading up to the choice; (ii) option
regret, referring to the treatment chosen; and
(iii) outcome regret, referring to the results of
the treatment. This study is the ﬁrst to develop
and validate separate regret subscales in order
to measure diﬀerent types of regret in the con-
text of an actual treatment decision for cancer,
that is prostate cancer.
Decision support and regret
Two opposing hypotheses can be formulated
with regard to the relation between decision
support and regret. The Decision Justiﬁcation
Theory10,11 posits that people tend to ask
themselves whether a choice was justiﬁed. A
‘careful and thorough (i.e. justiﬁed)’ decision is
expected to reduce feelings of regret.10 This
would suggest that a decision aid would
decrease regret.
The medical psychological model, on the
other hand, emphasizes the vulnerability of
patients. Patients may prefer to avoid threat-
ening or complicated information,12–14 and
they may prefer to avoid responsibility for
the possible negative consequences of the
choice.15,16 This would suggest that a decision
aid would increase regret, particularly in
patients experiencing a bad treatment out-
come. In line with this reasoning, we exam-
ined patients with bad outcome as a separate
group.
The study focused on two questions: (i)
whether a decision aid aﬀects regret, and (ii)
what the eﬀect is in patients with poor out-
come in terms of serious side-eﬀects.
Methods
Regret scales
To measure diﬀerent aspects of regret, 18
regret statements were developed (Table 1), in
part derived from previous studies.8,9,11,17–19
Patients indicated to what extent they agreed
with the statements, on a scale from 1 (com-
pletely disagree) to 5 (completely agree).
Three aspects of regret10 were distinguished:
(i) process regret, about the process leading
up to the choice, with items such as ‘I made
a well-informed choice’, and (ii) option
regret, about the treatment chosen, with items
such as ‘I would choose the same treatment
again’ and (iii) outcome regret, about the
treatment results, with items such as ‘I regret
the way the treatment turned out for me’.
Within each domain, items were averaged, re-
coding negatively worded items, to arrive at
a regret score of 1 (no regret) to 5 (strong
regret).
Trial design
The methods used in this trial have previously
been described elsewhere.20,21 This was a pro-
spective, parallel-group, multicentre random-
ized controlled trial between usual care and
usual care plus decision aid (Fig. 1). Patients
and caregivers could not be blinded to the
intervention.
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Setting and patients
From 2008 to 2011, patients with primary
localized prostate cancer (T1-3a), eligible for
both radical prostatectomy and radiotherapy,
were enrolled in three hospitals in the Nether-
lands, that is Radboud UMC Nijmegen,
Canisius Wilhelmina Hospital in Nijmegen and
Rijnstate Hospital in Arnhem. The latter are
two large non-academic centres. Given the
focus on the eﬀect of serious side-eﬀects,
patients wanting active surveillance were not
included in the study. Other exclusion criteria
were mental/cognitive problems, and inade-
quate knowledge of the Dutch language, as
assessed by the physician. The study was
approved by the ethics committees of the par-
ticipating hospitals.
Randomization
Enrolled patients were individually randomized
to (i) the usual care group, which discussed the
treatment choice with their specialist, or (ii) the
decision aid group, which, in addition, had the
decision aid presented by the researcher
(JvTG). Randomization was imbalanced (1 : 2)
to have a large enough decision aid group to
answer separate research questions, reported
elsewhere.20 Randomization was centralized to
avoid allocation bias and was blocked in
groups of 3 per hospital, thus stratifying for
hospital site.
Procedure
During the ﬁrst consultation, the urologist
mentioned that diﬀerent treatment options
were available. Patients who wanted active sur-
veillance were not eligible for the study. The
urologists mentioned the study to all remaining
eligible patients. For these patients, urologists
were instructed to describe the treatment
options brieﬂy and not to decide on a treat-
ment within the ﬁrst consultation. Written
informed consent was obtained after the
patients received additional information about
the study from the researcher. Subsequently,
patients were randomized to the usual care
group or the decision aid group, as described
above. The decision aid was presented to the
decision aid group only, about a week after the
Table 1 Items included in the regret subscales and their
mean scores on a 5-point scale1
Items Mean (SD)
Process regret At t2
I made a well-informed
choice
4.3 (0.8)
I want a clearer advice 2.2 (1.5)
I know the pros and
cons of the treatment
4.2 (0.8)
I want more information
about this decision
2.4 (1.4)
I am satisfied with the
information I received
4.2 (0.9)
I regret the way the
decision was reached
1.6 (1.2)
I weighed the pros and
cons of the treatment
against each other
4.4 (0.8)
Option regret At t3 At t4
It was the right decision 4.5 (0.7) 4.4 (0.7)
I regret the choice that
was made
1.5 (0.8) 1.5 (0.7)
I would go for the same
choice if I had to do it
over again
4.5 (0.7) 4.4 (0.8)
The treatment was the
wrong one for me
1.4 (0.6) 1.5 (0.8)
Looking back, another
treatment would’ve
been a better choice
1.5 (0.8) 1.6 (0.8)
I’m satisfied with the
treatment
4.4 (0.7) 4.3 (0.8)
The decision was a wise
one
4.4 (0.7) 4.3 (0.8)
Outcome regret
I regret the way the
treatment turned out
for me
1.8 (1.0) 1.8 (1.0)
The choice did me a lot
of harm
1.9 (1.1) 2.0 (1.1)
I’m satisfied with the
outcome of the
treatment
4.2 (0.9) 4.0 (1.0)
I regret the side effects
I experienced
3.0 (1.3) 2.9 (1.3)
t2 = 2 weeks after the decision was made, before treatment started.
t3 = 6 months after treatment.
t4 = 12 months after treatment.
1Item scores run from 1 (completely disagree) to 5 (completely agree).
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drop out due to
non-response (n = 5), deceased (n = 1)
left for treatment elsewhere (n = 2)
problems with questionnaires (n = 2)
drop out due to
non-response (n = 2), deceased (n = 1)
declined health (n = 1), stay abroad (n = 2)
study closure (n = 2)
drop out due to
non-response (n = 5)
study closure (n = 1)
 Twelve months Post-treatment (t4)
n = 140
 Six months Post-treatment (t3)
n = 146
TREATMENT
RP, BT or EBRT
Pretreatment assessment (t2)
n = 153
DECISION AID
Baseline Information (t1)
n = 163
DECISION AID group
drop out due to
non-response (n = 7)
drop out due to
non-response (n = 3)
study closure (n = 1)
drop out due to
non-response (n = 2)
dementia (n = 1)
study closure (n = 2)
 Twelve months Post-treatment (t4)
n = 61
 Six months Post-treatment (t3)
n = 66
TREATMENT
RP, BT or EBRT
Pretreatment assessment (t2)
n = 70
NO DECISION AID
Baseline Information (t1)
n = 77
USUAL CARE group
Randomisation 2:1
Included
n = 240
Invited to participate
(n = 307)
Declined (n = 35)
Not eligible (n = 31)
Figure 1 Patient flow and study design.
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consultation with the urologist, in a separate
consultation with the researcher. A single
researcher was used to obtain a standardized
presentation of the decision aid, thus minimiz-
ing the eﬀect of variation between caregivers.
Finally, all patients had a second consultation
with the urologist to discuss and decide on the
treatment choice.
Decision aid
The decision aid was developed according to
the IPDAS criteria.22 It explained that there
are diﬀerent treatment options with diﬀerent
pros and cons. Radical prostatectomy (by
open, laparoscopic or robot-assisted procedure)
and external beam radiotherapy were presented
to all patients. A third option, brachytherapy,
was presented only to eligible patients.
During the decision aid consultation with the
researcher, ﬁrst the main features of each treat-
ment were described in terms of procedures
involved. Risk information regarding the out-
come (bNED and survival) and side-eﬀects
(erectile, urinary and bowel) was based on a lit-
erature search20 and was provided in frequencies
and visual aid formats. Figure 2 shows the
information presented to most patients, that is
low-/intermediate-risk patients (PSA ≤ 20 and
Gleason ≤ 7 and T1T2). For patients at higher
Radical Brachy- Extern. beam
Prostatectomy therapy radiotherapy
Tumor control 81 out of 100 yes 80 out of 100 yes 76 out of 100 yes
No tumor detectable, 19 out of 100 no 20 out of 100 no 24 out of 100 no  
PSA remains low
(after 5 year)
Deceased of 3 out of 100 yes 5 out of 100 yes 6 out of 100 yes
prostate cancer 97 out of 100 no 95 out of 100 no 94 out of 100 no
(after 10 year)
Loss of erections 70 out of 100 35 out of 100 40 out of 100
Few to no 
erections
(after 2 year)
Severe urinary 9 out of 100 6 out of 100 2 out of 100
problems
viz. urine
incontinence
(after 2 year)
Severe bowel 2 out of 100 9 out of 100 9 out of 100
problems
viz. diarrhea
(after 2 year)
Figure 2 Decision aid for patients with PSA ≤ 20, Gleason ≤ 7, T1T2 and eligible for brachytherapy.
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risk (PSA > 20, Gleason > 7 and/or T3a), the
10-year risk of prostate cancer speciﬁc mortality
was adapted to 10 and 18% after radical prosta-
tectomy and external beam radiotherapy,
respectively. The information was also given to
the patients to take home.
To clarify values, patients were encouraged to
consider and discuss which pros and cons were
most important to them, both during the deci-
sion aid consultation and at home using the
written take-home information. The decision aid
has been described in more detail elsewhere.20
Outcome measures and follow-up
Questionnaires were sent at baseline (t1), that is
before the treatment choice was made; about
2 weeks later at pre-treatment (t2), that is after
the treatment was chosen, but before it was car-
ried out; and at 6 months (t3) and 12 months
(t4) after the surgery or the last radiotherapy
session. The ﬁrst questionnaire (t1) collected
baseline demographic and medical patient char-
acteristics. Decision-related outcome measures
(including regret) were assessed at t2 and/or
later (see below).
Patients’ characteristics
Tumour characteristics were extracted from the
patients’ medical records. Demographic vari-
ables were collected by questionnaire at t1.
Regret
Process regret was assessed at t2, right after
the decision-making process and before treat-
ment. Option regret and outcome regret were
assessed 6 and 12 months after treatment, at t3
and t4. These new regret scales range from 1
(no regret) to 5 (strong regret). In addition, the
Brehaut regret scale8 was assessed at t3 and t4,
ranging from 0 to 100, with items partly simi-
lar to our option regret scale.
Patient participation
At t2, perceived participation was assessed by
asking ‘Who decided on the treatment
choice?’,23 with answers ranging from ‘only the
physician’ to ‘only me’. To be able to correct
for possible baseline diﬀerences, baseline par-
ticipation preference was measured at t1: ‘Who
should, in your opinion, decide on the treat-
ment choice?’
Measures for validation
For the purpose of validating the regret scales,
anxiety and depression from the HADS24 and
Satisfaction–Uncertainty and Decision Control
from the Decisional Evaluation Scales18 were
assessed at t2, t3 and t4. The prostate-speciﬁc
HR-QOL was assessed at t1, t3 and t4 by
means of the EPIC scale.25 Scores ranged from
0 to 100, with higher scores reﬂecting better
functioning.
Statistical analysis
The validity of the newly developed regret
scales was examined by factor analysis on the
items (oblique rotation) and by analysing the
correlations with anxiety/depression, the Deci-
sion Evaluation Scales and health-related qual-
ity of life. In addition, Crohnbach’s alphas
were calculated. Furthermore, the regret scores
at 6 and 12 months after treatment were com-
pared to examine the reproducibility of the
scales.
To examine diﬀerences between the decision
aid group and the usual care group, t-tests
were used for continuous variables and chi-
square tests for ordinal or dichotomous vari-
ables. When data were missing, scale values
were calculated only if at least half of the items
were ﬁlled out, using the mean of the scored
items. For analysis, the participation level was
dichotomized as patient involved (‘together
with physician’, ‘mainly me’ or ‘only me’) vs.
physician decided (‘mainly physician’ or ‘only
physician’). The eﬀect of the decision aid on
regret was analysed by ANOVA.
Our primary research question for the inter-
vention was whether a decision aid had an
impact on regret. The eﬀect of the decision aid
on Brehaut regret, process regret, option regret
and outcome regret was analysed. Variables
were considered as possible confounding factors
if they were related to the regret score and
ª 2015 John Wiley & Sons Ltd
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diﬀered at baseline (P < 0.15) between the
decision aid group and the usual care group.
None of the demographic, medical or decision-
related variables, however, were signiﬁcantly
related to any of the regret scales. Therefore,
subsequent analyses (ANOVA) were not cor-
rected for confounders, and unadjusted means
are presented.
Our second a priori research question was
whether the eﬀect was diﬀerent in patients with
a bad treatment outcome. Therefore, the above
analyses were repeated on those patients that
had serious morbidity at t4. Serious morbidity,
that is poor functional outcome, was deﬁned as
a decrease of 15 points or more on the 100-
point urinary, bowel and/or sexual summary
EPIC score25 compared to the patient’s base-
line score. This criterion represents a minimal
important diﬀerence (MID) of half a standard
deviation.26 As standard deviations for the
scales ranged from 8 to 30, the upper limit of
30 was chosen, resulting in a MID of 15.
Results
Patients
The patients in this study were described in
more detail elsewhere.20,21 In total, 307 patients
were approached for the study, of whom 36
declined (12%), representing an informed con-
sent rate of 88%.21 The patients who declined
had a similar mean age as those who gave
informed consent (65 vs. 64 years). Of the
remaining 271 patients, 31 were not eligible; 14
were excluded because of other health prob-
lems, including cardiac problems and other
tumours; and 17 because they chose active sur-
veillance after all. Thus, 240 patients were
included. Patient characteristics in the decision
aid group and the usual care group were com-
parable for education, age, baseline physical
functioning and tumour characteristics.20 Within
the decision aid group, 91 patients (56%) were
eligible for brachytherapy and 16 patients
(10%) were high-risk patients. Overall, 169
(71%) were treated by RP, 28 (12%) by BT
and 42 (18%) by EBRT.20
The new regret scales
Tables 2 and 3 show results on the newly
developed regret scales. Process regret was
assessed by seven items. We categorized the
other eleven items a priori into two subscales,
option regret (7 items) and outcome regret (4
items); the loadings of the items in a factor
analysis conﬁrmed this categorization both
at 6 and 12 months after treatment (Table 2).
Cronbach’s alphas for the scales on process
regret and outcome regret were 0.95 and 0.79,
respectively. For the option regret scale,
Cronbach’s alpha was 0.94, compared to 0.83
for the validated Brehaut scale.
To quantify the reproducibility of the scales,
the scores at 6 months and 12 months after
treatment were compared. Correlations between
the scores at 6 and 12 months were 0.65 (P <
0.001) for outcome regret and 0.66 (P < 0.001)
for option regret, compared to 0.56 (P < 0.001)
for the Brehaut scale. This time diﬀerence is
quite large, resulting in an underestimate of the
reproducibility.
For the purpose of validating the regret scales,
correlations were examined of process regret (t2)
and option and outcome regret (t4) with other
measures at the corresponding point in time
(t2 or t4) (Table 3). Process regret, option regret
and outcome regret correlated signiﬁcantly with
the Decision Evaluation Scales (Satisfaction/
Uncertainty, Informed choice, Decision con-
trol), anxiety and depression (Table 3). Outcome
regret also correlated well with health-related
quality of life (urinary, bowel and sexual
scores). All correlations were in the expected
direction; that is, more regret was associated
with more anxiety/depression and with less deci-
sion satisfaction, less informed choice, less deci-
sion control and lower scores on health-related
QOL.
Effect of the decision aid
At baseline (t1), the preferred participation
level was high; 86 and 88% of the patients in
the decision aid group and the usual care
group, respectively, indicated at baseline that
ª 2015 John Wiley & Sons Ltd
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the patient should be involved in the treatment
decision (‘together with the physician’, or
‘mainly me’ or ‘only me’). At t2, 95% of the
patients in the decision aid group indicated that
they actually had been involved in the decision,
compared to 83% in the usual care group
(P = 0.002). As such, the decision aid had the
expected eﬀect on patient participation.
At the same time, the decision aid did not
aﬀect regret scores at t4, when analysed in all
patients (Table 4). In Table 5, regret was
examined separately in patients with or with-
out toxicity. Regret was not aﬀected in
patients without serious side-eﬀects. However,
in patients with serious side-eﬀects, if any-
thing, a trend to less option regret and less
Brehaut regret was found when a decision aid
had been used (P = 0.075 and P = 0.061,
respectively, and eﬀect sizes of 0.35 and 0.38,
respectively).
Discussion
The decision aid did not aﬀect regret in gen-
eral. However, in patients experiencing side-
eﬀects the use of the decision aid tended to
lower regret compared to usual care.
Development of the regret scales
As part of this study, we developed regret
subscales. The Crohnbach’s alphas and the
reproducibility of the regret scores were good.
For the purpose of validating these scales,
Table 3 Correlations of process regret (at t2) and option and
outcome regret (at t4) with Decision Evaluation Scales
(Satisfaction/Uncertainty, Decision control, Informed choice),
anxiety and depression. Perceived responsibility and quality
of life (QOL) scores at the corresponding point in time (t2
or t4)
Process
regret (t2)
Option
regret (t4)
Outcome
regret (t4)
Satisfaction/
Uncertainty
0.641 0.561 0.431
Decision control 0.571 0.611 0.351
Informed choice 0.971 NA NA
Anxiety 0.202 0.241 0.261
Depression 0.192 0.251 0.361
Feeling responsible
for decision
0.381 0.401 0.202
Feeling responsible
for outcome
0.093 0.202 0.251
QOL scores (EPIC)3
Urinary score NA 0.182 0.461
Bowel score NA 0.182 0.251
Sexual score NA 0.103 0.271
NA, not assessed at given time.
1P < 0.001, 2P < 0.02, 3Not Significant. 4Higher EPIC scores reflect
better quality of life.
Table 2 Factor loadings (Pattern Matrix) of 11 items in two
subscales
Option
regret
Outcome
regret
At 6 months after treatment
It was the right decision 0.78
I regret the choice that was made 0.62
I would go for the same choice if I
had to do it over again
0.86
The treatment was the wrong one
for me
0.90
Looking back, another treatment
would’ve been a better choice
0.71
I’m satisfied with the treatment 0.63 0.30
The decision was a wise one 0.74
I regret the way the treatment
turned out for me
0.67
The choice did me a lot of harm 0.70
I’m satisfied with the outcome of
the treatment
0.42 0.37
I regret the side effects I experienced 0.88
At 12 months after treatment
It was the right decision 0.82
I regret the choice that was made 0.85
I would go for the same choice if I
had to do it over again
0.91
The treatment was the wrong one
for me
0.91
Looking back, another treatment
would’ve been a better choice
0.82
I’m satisfied with the treatment 0.70
The decision was a wise one 0.90
I regret the way the treatment
turned out for me
0.66
The choice did me a lot of harm 0.72
I’m satisfied with the outcome of
the treatment
0.32 0.57
I regret the side effects I
experienced
0.91
Extraction Method: Principal Component Analysis. Rotation Method:
Oblimin with Kaiser Normalization.
Correlations smaller than 0.30 were suppressed.
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their correlations with other measures were
examined. All correlations were in the
expected direction; that is, more regret was
associated with more anxiety/depression and
with less decisional conﬂict and lower QOL.
These ﬁndings conﬁrm the concurrent validity
of our regret scales.
Previous research showed a shift in how
patients evaluated the decision-making pro-
cess, depending on the treatment outcome:
the better the outcome of the treatment, the
easier they perceived the decision-making pro-
cess in retrospect.27 Others suggested that
patients experiencing problems after treatment
may shift more responsibility about the treat-
ment decision to others and may believe to
have had little choice.28 To avoid such bias
by treatment experience, process regret was
only measured right after the decision-making
process (t2).
Relation between decision support and regret
Previous studies examining the eﬀect of decision
support reported less regret5,29,30 or no eﬀect,6,7
which is in line with our results. In our study,
the lack of an eﬀect on regret in general could
not be attributed to the decision aid being inef-
fective, because several eﬀects of the decision aid
were found on the level of participation and on
treatment choice, as reported elsewhere.20 Thus,
with regard to our ﬁrst research question, we
can conclude that the decision aid did not induce
regret in general.
However, a diﬀerent result was found for an
important patient group, that is those with
serious side-eﬀects. For these patients, a trend
to less regret was found when a decision aid
had been used compared to usual care. This
eﬀect was not caused by a diﬀerence in out-
come or treatment choice between the decision
aid group and the usual care group. In itself,
poor outcome (in terms of functional or bio-
chemical outcome) can lead to more regret, as
Table 4 Regret scores in the decision aid group and the
usual care group (scores and analyses unadjusted)
Regret scales
Decision aid
Mean (SD)
Usual care
Mean (SD) P
Process regret1
t2 (N = 219) 1.85 (0.50) 1.83 (0.54) 0.78
Option regret1
t3 (N = 210) 1.49 (0.55) 1.53 (0.54) 0.59
t4 (N = 201) 1.58 (0.65) 1.68 (0.62) 0.30
Outcome regret1
t3 (N = 209) 2.06 (0.82) 2.22 (0.86) 0.19
t4 (N = 201) 2.16 (0.86) 2.29 (0.91) 0.32
Brehaut regret2
t3 (N = 212) 14.2 (14.9) 15.7 (15.3) 0.52
t4 (N = 201) 16.1 (16.2) 19.4 (16.6) 0.19
t2 = 2 weeks after the decision was made, before treatment
started.
t3 = 6 months after treatment.
t4 = 12 months after treatment.
1Regret scales run from 1 (=no regret) to 5 (=strong regret).
2Brehaut regret scale runs from 0 to 100 with higher scores
reflecting more regret.
Table 5 Regret scores for patients with and without serious
side-effects at t4, 12 months after treatment, in the
decision aid group and the usual care group (scores and
analyses unadjusted)
Decision aid
Mean (SD)
Usual care
Mean (SD) P
Effect
size
Without serious side-effects1
Option
regret3
(N = 61)
1.42 (0.71) 1.40 (0.42) 0.91 0.03
Outcome
regret3
(N = 61)
1.76 (0.75) 1.81 (0.49) 0.82 0.07
Brehaut
regret2
(N = 61)
11.4 (17.8) 12.8 (11.0) 0.76 0.09
With serious side-effects1
Option
regret3
(N = 120)
1.61 (0.57) 1.83 (0.70) 0.075 0.354
Outcome
regret3
(N = 120)
2.35 (0.88) 2.58 (1.04) 0.223 0.254
Brehaut
regret2
(N = 121)
17.8 (14.7) 23.9 (18.9) 0.061 0.384
1Having serious side-effects was defined as a decrease of at least
15 points from baseline in EPIC score for either urinary, bowel and/
or sexual functioning.
2Brehaut regret scale runs from 0 to 100 with higher scores
reflecting more regret.
3Option and outcome regret scales run from 1 (=no regret) to 5
(=strong regret).
4These effect sizes are considered small (0.2) to medium (0.5)
effects.
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is illustrated in Table 5 and as has been shown
by previous research.31 The decision aid, how-
ever, did not inﬂuence functional outcome, as
a similar proportion of patients were faced
with serious side-eﬀects in the decision aid
group and the control group, that is 66.7 and
66.0%, respectively. Secondly, to control for
the eﬀect of the decision aid on treatment
choice, we separately analysed the data of
patients who had all received the same treat-
ment (i.e. radical prostatectomy). Again, we
found no eﬀect of the decision aid in patients
with good functional outcome, and again, the
decision aid was associated with a trend to less
option and Brehaut regret in patients with
poor functional outcome, with identical eﬀect
sizes of 0.35 and 0.38, respectively. These
eﬀects support the Decision Justiﬁcation
Theory,10,11 in that decision support may help
patients to reach a careful decision, thus reduc-
ing feelings of regret later on. One could
hypothesize that regret is also inﬂuenced by
risk classiﬁcation, with higher risk patients pos-
sibly experiencing less regret when faced with
side-eﬀects. Analyses showed that in patients
with side-eﬀects, regret did not diﬀer between
risk groups. Option regret, for example, is
1.71, 1.66 and 1.58 for low, intermediate and
high risk, respectively (P = 0.75). However,
explorative analyses with risk group included
in the model for option regret, showed a main
eﬀect of decision aid (P = 0.047) and an inter-
action between risk group and decision aid
(P = 0.013). In the setting of side-eﬀects, the
decision aid had more of a lowering eﬀect on
regret in intermediate- or high-risk patients
than in low-risk patients. Option regret with or
without decision aid was 1.77 vs. 1.53, respec-
tively, in low-risk patients, 1.49 vs. 2.00 in
intermediate-risk patients and 1.39 vs. 1.92 in
high-risk patients.
Limitations and strengths
The study was carried out in the context of
prostate cancer, limiting generalization to other
cancer types. Another limitation is the follow-
up duration of 1 year post-treatment, which
may be too short to fully capture the develop-
ment of regret. In addition, the eﬀect of poor
outcome could only be analysed in terms of
functional outcome, that is side-eﬀects. Poor
biochemical outcome such as PSA relapse was
too scarce within the ﬁrst year to be analysed
separately. Furthermore, there is debate about
the presentation of probabilities. The pie chart
format in itself has been reported to lead to
more errors and longer reaction times com-
pared to other formats.32 However, adding
numbers to the pie charts, as in our risk pre-
sentation, eliminated this negative eﬀect.33 As
numbers were provided next to the pie charts,
our format appears to be suitable.
Another limitation is the exclusion of
patients preferring active surveillance. The sec-
ond research question in this study focused on
the eﬀect of serious side-eﬀects. The treatment
option of active surveillance does not lead to
side-eﬀects. Therefore, patients on active sur-
veillance were not suited for the second
research question and were not included in the
study. Moreover, at the time of the develop-
ment of the decision aid, outcome data were
not available for active surveillance in the same
detail as for other treatments, and therefore,
this option was not included in the overview
(Fig. 2). Still, exclusion of patients on active
surveillance is a limitation, as they constitute a
relevant patient group which may also be at
risk for regret.
The values clariﬁcation in decision aids can
be implicit (e.g. stimulating the patient to think
about which treatment aspects are most impor-
tant to him) or explicit (rating or ranking
diﬀerent treatment aspects). Our approach
involves an implicit values clariﬁcation rather
than an explicit one. In recent years, there is
debate on whether explicit values clariﬁcation
exercises actually improve the quality of deci-
sion making.34,35
A strength of this study is that patient par-
ticipation and other eﬀects of the decision aid
were assessed before the treatment was exe-
cuted, avoiding bias by treatment experiences.
In addition, this is a prospective study, elimi-
nating recall bias. This study is the ﬁrst to
ª 2015 John Wiley & Sons Ltd
Health Expectations, 19, pp.459–470
Does a decision aid affect regret?, J J van Tol-Geerdink et al.468
measure diﬀerent types of regret in the context
of an actual treatment decision. Most studies
to date used the Brehaut scale, focusing on
option regret. Our study provided new insights
for two additional aspects of regret, namely
process regret and outcome regret.
Conclusion
Within the context of treatment choice for
prostate cancer, regret was not increased by a
decision aid in this study, nor in previous
studies.5–7,29 If anything, our data and reports
by others5,29,30 suggest that decision support
may tend to lower regret, particularly for an
important patient group, that is patients with
serious morbidity. Exploratory analyses suggest
that intermediate- and high-risk patients bene-
ﬁtted most from the decision aid. Although
more research is needed, the newly developed
regret scales may be of value in distinguishing
between diﬀerent aspects of regret, that is
process, option and outcome regret.
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